Effect of continuous positive airway pressure (CPAP) therapy on IL-23 in patients with obstructive sleep apnea.
Obstructive sleep apnea syndrome (OSAS) is a common sleep disorder characterized by repeated episodes of apnea and hypopnea during sleep. Continuous positive airway pressure (CPAP) is the most effective method for treating OSAS and alleviating the patients' symptoms. The aim of this study was to assess the effect of 3-month CPAP therapy on serum levels of IL-23 in patients with OSAS. Twenty-three patients with newly diagnosed moderate-to-severe OSAS who had not yet started nasal CPAP treatment were prospectively enrolled. All of the subjects underwent simple spirometry and an overnight sleep study. Twenty-seven healthy individuals without OSAS were also recruited as the control group. Serum IL-23 and C-reactive protein (CRP) levels were measured before and after 3 months of CPAP therapy. There was no significant difference between moderate and severe OSAS patients in IL-23 and CRP, but both parameters were significantly higher than control group. The CPAP treatment produced a significant decrease in the levels of the inflammatory mediators CRP and IL-23 in patients. Changes in IL-23 were positively correlated with changes in AHI and in CRP. In conclusion, based on these results, serum IL-23 levels reflect OSAS-related systemic inflammation and are a useful marker for improvement in OSAS following CPAP therapy.
Department of Biochemistry, Faculty of Medicine, Bulent Ecevit University, Zonguldak, Turkey. drcanmurat@yahoo.com.
Murat
M
Can
Department of Chest Diseases, Faculty of Medicine, Bulent Ecevit University, Zonguldak, Turkey.
Fırat
F
Uygur
Department of Chest Diseases, Faculty of Medicine, Bulent Ecevit University, Zonguldak, Turkey.
Hakan
H
Tanrıverdi
Department of Public Health, Faculty of Medicine, Bulent Ecevit University, Zonguldak, Turkey.
Bilgehan
B
Acıkgoz
Department of Emergency Medicine, Umraniye Education and Training Hospital, Zonguldak, Turkey.
Barıs
B
Alper
Department of Biochemistry, Faculty of Medicine, Bulent Ecevit University, Zonguldak, Turkey.
Berrak
B
Guven
D000368:Aged; D002097:C-Reactive Protein / Q000378:metabolism*; D045422:Continuous Positive Airway Pressure; D065187:Controlled Before-After Studies; D018450:Disease Progression; D015536:Down-Regulation; D005260:Female; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism*; D053759:Interleukin-23 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D020181:Sleep Apnea, Obstructive / Q000276:immunology / Q000628:therapy*; D013147:Spirometry
D018836:Inflammation Mediators; D053759:Interleukin-23; D002097:C-Reactive Protein
CPAP; CRP; IL-23; OSAS
Clin Chem. 1972 Jun;18(6):499-502
4337382
Circulation. 2005 Oct 25;112(17 ):2660-7
16246965
Eur Arch Otorhinolaryngol. 2014 Apr;271(4):825-31
23995706
Cytokine Growth Factor Rev. 2015 Oct;26(5):569-78
26195433
Sleep Breath. 2012 Mar;16(1):217-21
21331508
Eur Heart J. 2004 May;25(9):735-41
15120883
Lancet. 2005 Mar 19-25;365(9464):1046-53
15781100
Trends Immunol. 2013 Nov;34(11):548-55
23954142
Evid Based Complement Alternat Med. 2014;2014:637969
24971150
Eur J Immunol. 2012 Sep;42(9):2263-73
22949325
Clin Exp Immunol. 2009 Aug;157(2):316-24
19604272
Chest. 2006 Feb;129(2):233-7
16478836
Sleep Med. 2013 Nov;14(11):1139-50
24054505
Mediators Inflamm. 2012;2012:815308
23345934
Sleep. 2016 Oct 01;39(10 ):1883-1890
27397567
Am J Med. 2009 Dec;122(12):1122-7
19958890
J Biol Regul Homeost Agents. 2012 Jan-Mar;26(1 Suppl):S53-61
22691251
Sleep Breath. 2003 Sep;7(3):105-10
14569521
Sleep. 2013 May 01;36(5):763-768C
23633759
Immunology. 2012 Feb;135(2):112-24
22044352
Circulation. 2003 Mar 4;107(8):1129-34
12615790
Sleep Med Rev. 2000 Oct;4(5):411-33
17210275
Int Arch Allergy Immunol. 2012;159(2):183-6
22678234
Nat Rev Immunol. 2014 Sep;14(9):585-600
25145755
Sleep Med. 2012 Jun;13(6):583-8
22521311